Consonance-HFW Acquisition Corp.
Completed
Follow
Detailed Information
Information on this SPAC.
- Sponsors
- IPO Size
- $80M
- Underwriters
- Focus
- Life Sciences, Biotech
- SEC Filings
- 1824893
- Public Embarc Page
- https://embarc.com/capital/spac/1824893/CHFW/consonance-hfw-acquisition
- IPO Ticker
- CHFW
SPAC Leadership
Information on the SPAC leadership.
- ChairmanMitchell Blutt, M.D.
- CEOGad Soffer
- CFOKevin Livingston
- DirectorBenny Soffer, M.D.
- Business DevelopmentJoshua House
- DirectorDonald J. Santel
- DirectorChristopher Haqq, M.D., Ph.D.
- DirectorJennifer Jarrett
Target Information
Information on the SPAC target for merger.
- Company
- Surrozen
- Presentation
- Investor Presentation (SEC) on 2021-04-15
- Description
- Surrozen is a "company pioneering targeted therapeutics that selectively activate the Wnt pathway for tissue repair and regeneration."